Evidence map›Paper›PMID 39488633›Full record

ArticleEuropean biophysics journal : EBJ2024

Exploring characteristic features for effective HCN1 channel inhibition using integrated analytical approaches: 3D QSAR, molecular docking, homology modelling, ADME and molecular dynamics.

Shiwani Sharma, Priyanka Rana, Vijayta Dani Chadha, Neelima Dhingra, Tanzeer Kaur

Abstract read
PubMed Publisher
In one paragraph

Article in European biophysics journal : EBJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shiwani SharmaDepartment of Biophysics, Panjab University, Chandigarh, 160014, India.
Priyanka RanaUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India.
Vijayta Dani ChadhaCentre for Nuclear Medicine, Panjab University, Chandigarh, 160014, India.
Neelima DhingraUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India. neelimad08@gmail.com.
Tanzeer KaurDepartment of Biophysics, Panjab University, Chandigarh, 160014, India. tanzeer.kaur@pu.ac.in.ORCID http://orcid.org/0000-0003-2935-7575

Funding

Indian Council of Medical Research 5/4-5/188/Neuro/2019-NCD-1
6 · The paper itself

Abstract

Neuropathic pain (NP) is characterized by hyperalgesia, allodynia, and spontaneous pain. Hyperpolarization-activated cyclic nucleotide-gated (HCN) channel involved in neuronal hyperexcitability, has emerged as an important target for the drug development of NP. HCN channels exist in four different isoforms, where HCN1 is majorly expressed in dorsal root ganglion having an imperative role in NP pathophysiology. A specific HCN1 channel inhibitor will hold the better potential to treat NP without disturbing the physiological roles of other HCN isoforms. The main objective is to identify and analyze the chemical properties of scaffolds with higher HCN1 channel specificity. The 3D-QSAR studies highlight the hydrophobic & hydrogen bond donor groups enhance specificity towards the HCN1 channel. Further, the molecular interaction of the scaffolds with the HCN1 pore was studied by generating an open-pore model of the HCN1 channel using homology modelling and then docking the molecules with it. In addition, the important residues involved in the interaction between HCN1 pore and scaffolds were also identified. Moreover, ADME predictions revealed that compounds had good oral bioavailability and solubility characteristics. Subsequently, molecular dynamics simulation studies revealed the better stability of the lead molecules A7 and A9 during interactions and ascertained them as potential drug candidates. Cumulative studies provided the important structural features for enhancing HCN1 channel-specific inhibition, paving the way to design and develop novel specific HCN1 channel inhibitors.

Indexed as

Hyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsMolecular Docking SimulationMolecular Dynamics SimulationQuantitative Structure-Activity RelationshipAmino Acid SequenceHumansPotassium ChannelsStructural Homology, ProteinHyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsPotassium Channels3D-QSARDockingHCN channelHomology modellingNeuropathic pain

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.